Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim Evaluation and International Prognostic Index: A Multicenter Retrospective Study

The baseline International Prognostic Index (IPI) is not sufficient for the initial risk stratification of patients with diffuse large B-cell lymphoma (DLBCL) treated with R‐CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone). The aims of this study were to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Xue, Liu, Xiaoqian, Li, Xiaomei, Li, Yahan, Lu, Dongyue, Sun, Xue, Li, Ying, Hu, Shunfeng, Zhang, Yuanfeng, Zhou, Xiangxiang, Wang, Xin, Chen, Haiping, Fang, Xiaosheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716489/
https://www.ncbi.nlm.nih.gov/pubmed/34976802
http://dx.doi.org/10.3389/fonc.2021.754964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716489/
https://www.ncbi.nlm.nih.gov/pubmed/34976802
http://dx.doi.org/10.3389/fonc.2021.754964

Ejemplares similares